Evidence map›Paper›PMID 38689506›Full record

ArticleAnnals of clinical and translational neurology2024

Clinical heterogeneity within the ALS-FTD spectrum in a family with a homozygous optineurin mutation.

Tandis Parvizi, Sigrid Klotz, Omar Keritam, Haluk Caliskan, Sophie Imhof, Theresa König, Lukas Haider, Tatjana Traub-Weidinger, Matias Wagner, Theresa Brunet and 6 more

Abstract readCase Reports
In one paragraph

Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tandis Parvizi *Department of Neurology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-6989-7539
Sigrid Klotz *Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
Omar KeritamDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Haluk CaliskanDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Sophie ImhofDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Theresa KönigDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Lukas HaiderDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Tatjana Traub-WeidingerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Matias WagnerInstitute of Neurogenomics, Helmholtz Centrum, Munich, Germany.ORCID 0000-0002-4454-8823
Theresa BrunetInstitute of Human Genetics, Technical University Munich, Munich, Germany.ORCID 0000-0002-5183-780X
Melanie BruggerInstitute of Human Genetics, Technical University Munich, Munich, Germany.ORCID 0000-0002-6920-8550
Alexander ZimprichDepartment of Neurology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-1668-5177
Jakob RathDepartment of Neurology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-6581-4572
Elisabeth StögmannDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Ellen GelpiComprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2948-4187
Hakan CetinDepartment of Neurology, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMutations in the gene encoding for optineurin (OPTN) have been reported in the context of different neurodegenerative diseases including the amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) spectrum. Based on single case reports, neuropathological data in OPTN mutation carriers have revealed transactive response DNA-binding protein 43 kDa (TDP-43) pathology, in addition to accumulations of tau and alpha-synuclein. Herein, we present two siblings from a consanguineous family with a homozygous frameshift mutation in the OPTN gene and different clinical presentations.

methodsBoth affected siblings underwent (i) clinical, (ii) neurophysiological, (iii) neuropsychological, (iv) radiological, and (v) laboratory examinations, and (vi) whole-exome sequencing (WES). Postmortem histopathological examination was conducted in the index patient, who deceased at the age of 41.

resultsThe index patient developed rapidly progressing clinical features of upper and lower motor neuron dysfunction as well as apathy and cognitive deterioration at the age of 41. Autopsy revealed an ALS-FTLD pattern associated with prominent neuronal and oligodendroglial TDP-43 pathology, and an atypical limbic 4-repeat tau pathology reminiscent of argyrophilic grain disease. The brother of the index patient exhibited behavioral changes and mnestic deficits at the age of 38 and was diagnosed with behavioral FTD 5 years later, without any evidence of motor neuron dysfunction. WES revealed a homozygous frameshift mutation in the OPTN gene in both siblings (NM_001008212.2: c.1078_1079del; p.Lys360ValfsTer18).

interpretationOPTN mutations can be associated with extensive TDP-43 pathology and limbic-predominant tauopathy and present with a heterogeneous clinical phenotype within the ALS-FTD spectrum within the same family.

Indexed as

Amyotrophic Lateral SclerosisCell Cycle ProteinsFrontotemporal DementiaMembrane Transport ProteinsAdultFemaleFrameshift MutationHomozygoteHumansMalePedigreeSiblingsTranscription Factor TFIIIACell Cycle ProteinsMembrane Transport ProteinsOPTN protein, humanTranscription Factor TFIIIA

Identifiers

PMID38689506
PMCPMC11187959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.